These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20062589)

  • 1. Safety of trastuzumab (Herceptin) during pregnancy: two case reports.
    Goodyer MJ; Ismail JR; O'Reilly SP; Moylan EJ; Ryan CA; Hughes PA; O'Connor A
    Cases J; 2009 Dec; 2():9329. PubMed ID: 20062589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab in the treatment of advanced breast cancer: single-center experience.
    Mrsić M; Grgić M; Budisić Z; Podolski P; Bogdanić V; Labar B; Jakić-Razumović J; Restek-Samarzija N; Gosev M
    Ann Oncol; 2001; 12 Suppl 1():S95-6. PubMed ID: 11521730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
    Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
    Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
    Smith IE
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S3-10. PubMed ID: 11989525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer.
    Buiga P; Elson A; Tabernero L; Schwartz JM
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy--Case report and updated literature review.
    Shrim A; Garcia-Bournissen F; Maxwell C; Farine D; Koren G
    Reprod Toxicol; 2007 Jun; 23(4):611-3. PubMed ID: 17399946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Case Report on Treatment of Metastatic Breast Cancer with Trastuzumab during Pregnancy].
    Rasenack R; Gaupp N; Rautenberg B; Stickeler E; Prömpeler H
    Z Geburtshilfe Neonatol; 2016 Apr; 220(2):81-3. PubMed ID: 27111595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials of Herceptin(R) (trastuzumab).
    Baselga J
    Eur J Cancer; 2001 Jan; 37 Suppl 1():18-24. PubMed ID: 11342196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
    Lambertini M; Martel S; Campbell C; Guillaume S; Hilbers FS; Schuehly U; Korde L; Azim HA; Di Cosimo S; Tenglin RC; Huober J; Baselga J; Moreno-Aspitia A; Piccart-Gebhart M; Gelber RD; de Azambuja E; Ignatiadis M
    Cancer; 2019 Jan; 125(2):307-316. PubMed ID: 30335191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.
    Zhang JL; Yao Q; Chen Y Wang JH; Wang H; Fan Q; Ling R; Yi J; Wang L
    Genet Mol Res; 2015 Mar; 14(1):2099-103. PubMed ID: 25867356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line Herceptin monotherapy in metastatic breast cancer.
    Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ
    Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
    Burris HA
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios.
    Watson WJ
    Obstet Gynecol; 2005 Mar; 105(3):642-3. PubMed ID: 15738038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Trastuzumab (Herceptin) in a patient with locally recurrent breast cancer after cardiac failure caused by severe cytotoxic pretreatment.
    Gerber B; Krause A; Markmann S; Reimer T; Fietkau R; Müller H
    Oncology; 2001; 61(4):271-4. PubMed ID: 11721173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis.
    Xia LY; Hu QL; Zhou Q
    BMC Womens Health; 2021 Apr; 21(1):169. PubMed ID: 33882925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
    Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.
    Cook-Bruns N
    Oncology; 2001; 61 Suppl 2():58-66. PubMed ID: 11694789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.